Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Salvage whole brain radiotherapy after methotrexate failure in primary cns lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

BFBeatrice FregoneseLSLauren SchaffLFLorenzo Falchi

Discussion

Loading...

Member takes

Overview

Retrospective cohort study found median overall survival of 17.5 months after whole brain radiotherapy in primary CNS lymphoma, indicating it may be a viable salvage option post-methotrexate failure.

Key Points

  • Median overall survival reached 17.5 months following whole brain radiotherapy in 52 patients with primary CNS lymphoma.
  • Patients aged 50 and younger showed 2-year overall survival of 70%, compared to 37% in older patients.
  • Retrospective cohort analysis evaluated the effectiveness of radiotherapy post-methotrexate treatment at a single cancer center.
  • Findings suggest that radiation dose may not significantly influence overall survival in salvage treatments for resistant lymphoma.

Cite This Study

Fregonese et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d4cbhttps://doi.org/10.1182/blood-2025-3679
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The whole brain radiotherapy is a safe and effective backbone in primary central nervous system lymphoma: A 23-year real-world experience2025
  2. 2Treatment patterns and outcomes of primary central nervous system lymphoma treated with high-dose methotrexate with or without autologous stem cell transplantation or whole brain radiation in the rea-world setting2025
  3. 3Outcomes of primary CNS lymphoma treated with combined immunochemotherapy with whole-brain radiotherapy2025
  4. 4Lenalidomide–rituximab with high-dose methotrexate for treatment of patients with newly diagnosed primary cns lymphoma: a promising first-line approach2025 · 1 citations
  5. 5Management of Newly Diagnosed Primary Central Nervous System Lymphoma2025